TREATMENT OF APLASTIC ANEMIA WITH ANTI-THYMOCYTE GLOBULIN AND CYCLOSPORIN A

用抗胸腺细胞球蛋白和环孢菌素 A 治疗再生障碍性贫血

• 批准号: 3752284
• 负责人: S ROSENFELD
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3752284
• 关键词: aplastic anemia; blood disorder chemotherapy; combination chemotherapy; cyclosporines; human subject; human therapy evaluation; immunoglobulins; immunohematology; immunosuppressive; immunotherapy; thymus

Aplastic anemia is characterized by peripheral pancytopenia and a hypocellular bone marrow. The treatment of choice is allogeneic bone marrow transplantation from an HLA-matched sibling. Unfortunately, the majority of affected patients are ineligible for this procedure because of lack of a suitable donor, advanced age, or lack of financial resources. Currently, the best treatment for these individuals is immunosuppression. in protocol 90-H-146 we are trying to optimize the immunosuppressive regimen by combining four days of anti-thymocyte globulin (ATG) and six months of cyclosporine A. We have enrolled a total of 53 patients and are in the process Of analyzing the data for publication. Patients are admitted to the NHLBI Hematology Branch clinical service located on 2W. Attending responsibilities rotate among the NHLBI staff as well as Clinical Center staff, including Transfusion Medicine. There was no attending from CPD last year, but three of the Hematology senior staff are scheduled to attend in the coming year. Patients are cared for by Hematology fellows. All data analysis is performed by Dr. Rosenfeld.

再生障碍性贫血的特征是外周全血细胞减少， 骨髓细胞减少治疗的选择是同种异体骨 来自HLA匹配同胞的骨髓移植可惜 大多数受影响的患者不适合进行该手术 由于缺乏合适的捐赠者，高龄，或缺乏 金融资源目前，最好的治疗方法是 个体是免疫抑制。在90-H-146协议中， 为了优化免疫抑制方案， 抗胸腺细胞球蛋白（ATG）和6个月的环孢素A。我们 共招募了53名患者， 分析数据以供发布。 患者入住NHLBI血液学分支临床服务中心 位于2 W。出席职责在NHLBI工作人员之间轮换 以及临床中心的工作人员，包括输血医学。 去年芝加哥警署没有主治医生，但是血液科有三个 高级工作人员定于明年参加。患者 由血液学研究员照顾。所有数据分析均由Dr. 罗森菲尔德